Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

miR-101 suppresses the development of MLL-rearranged acute myeloid leukemia.

Gonzales-Aloy E, Connerty P, Salik B, Liu B, Woo AJ, Haber M, Norris MD, Wang J, Wang JY.

Haematologica. 2019 Feb 21. pii: haematol.2018.209437. doi: 10.3324/haematol.2018.209437. [Epub ahead of print]

2.

Cystobactamids 920-1 and 920-2: Assignment of the Constitution and Relative Configuration by Total Synthesis.

Planke T, Moreno M, Hüttel S, Fohrer J, Gille F, Norris MD, Siebke M, Wang L, Müller R, Kirschning A.

Org Lett. 2019 Mar 1;21(5):1359-1363. doi: 10.1021/acs.orglett.9b00058. Epub 2019 Feb 8.

PMID:
30735398
3.

Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma.

Gamble LD, Purgato S, Murray J, Xiao L, Yu DMT, Hanssen KM, Giorgi FM, Carter DR, Gifford AJ, Valli E, Milazzo G, Kamili A, Mayoh C, Liu B, Eden G, Sarraf S, Allan S, Di Giacomo S, Flemming CL, Russell AJ, Cheung BB, Oberthuer A, London WB, Fischer M, Trahair TN, Fletcher JI, Marshall GM, Ziegler DS, Hogarty MD, Burns MR, Perini G, Norris MD, Haber M.

Sci Transl Med. 2019 Jan 30;11(477). pii: eaau1099. doi: 10.1126/scitranslmed.aau1099.

PMID:
30700572
4.

A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction.

Somers K, Wen VW, Middlemiss SMC, Osborne B, Forgham H, Jung M, Karsa M, Clifton M, Bongers A, Gao J, Mayoh C, Raoufi-Rad N, Kusnadi EP, Hannan KM, Scott DA, Kwek A, Liu B, Flemming C, Chudakova DA, Pandher R, Failes TW, Lim J, Angeli A, Osterman AL, Imamura T, Kees UR, Supuran CT, Pearson RB, Hannan RD, Davis TP, McCarroll J, Kavallaris M, Turner N, Gudkov AV, Haber M, Norris MD, Henderson MJ.

Oncogene. 2019 Jan 22. doi: 10.1038/s41388-018-0666-5. [Epub ahead of print]

PMID:
30670779
5.

Transcriptome profiling of caspase-2 deficient EμMyc and Th-MYCN mouse tumors identifies distinct putative roles for caspase-2 in neuronal differentiation and immune signaling.

Dorstyn L, Hackett-Jones E, Nikolic A, Norris MD, Lim Y, Toubia J, Haber M, Kumar S.

Cell Death Dis. 2019 Jan 22;10(2):56. doi: 10.1038/s41419-018-1296-0.

6.

JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis.

Lynch JR, Salik B, Connerty P, Vick B, Leung H, Pijning A, Jeremias I, Spiekermann K, Trahair T, Liu T, Haber M, Norris MD, Woo AJ, Hogg P, Wang J, Wang JY.

Leukemia. 2019 Jan 8. doi: 10.1038/s41375-018-0354-z. [Epub ahead of print]

PMID:
30622285
7.

Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma.

Fultang L, Gamble LD, Gneo L, Berry AM, Egan SA, De Bie F, Yogev O, Eden GL, Booth S, Brownhill S, Vardon A, McConville CM, Cheng PN, Norris MD, Etchevers HC, Murray J, Ziegler DS, Chesler L, Schmidt R, Burchill SA, Haber M, De Santo C, Mussai F.

Cancer Res. 2019 Feb 1;79(3):611-624. doi: 10.1158/0008-5472.CAN-18-2139. Epub 2018 Dec 13.

PMID:
30545920
8.

Too many targets, not enough patients: rethinking neuroblastoma clinical trials.

Fletcher JI, Ziegler DS, Trahair TN, Marshall GM, Haber M, Norris MD.

Nat Rev Cancer. 2018 Jun;18(6):389-400. doi: 10.1038/s41568-018-0003-x. Review.

PMID:
29632319
9.

Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.

Ooi CY, Carter DR, Liu B, Mayoh C, Beckers A, Lalwani A, Nagy Z, De Brouwer S, Decaesteker B, Hung TT, Norris MD, Haber M, Liu T, De Preter K, Speleman F, Cheung BB, Marshall GM.

Cancer Res. 2018 Jun 15;78(12):3122-3134. doi: 10.1158/0008-5472.CAN-17-3034. Epub 2018 Apr 2.

PMID:
29610116
10.

Relation of Increased Epicardial Fat After Fontan Palliation to Cardiac Output and Systemic Ventricular Ejection Fraction.

Lubert AM, Lu JC, Rocchini AP, Norris MD, Yu S, Agarwal PP, Ghadimi Mahani M, Dorfman AL.

Am J Cardiol. 2018 Apr 1;121(7):862-866. doi: 10.1016/j.amjcard.2017.12.026. Epub 2018 Jan 9.

PMID:
29433731
11.

Total synthesis and structural elucidation of spongosoritin A.

Alcock LJ, Norris MD, Perkins MV.

Org Biomol Chem. 2018 Feb 21;16(8):1351-1358. doi: 10.1039/c7ob03150e.

PMID:
29404557
12.

A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.

Sutton R, Venn NC, Law T, Boer JM, Trahair TN, Ng A, Den Boer ML, Dissanayake A, Giles JE, Dalzell P, Mayoh C, Barbaric D, Revesz T, Alvaro F, Pieters R, Haber M, Norris MD, Schrappe M, Dalla Pozza L, Marshall GM.

Br J Haematol. 2018 Feb;180(4):550-562. doi: 10.1111/bjh.15056. Epub 2017 Nov 30.

PMID:
29194562
13.

Long-Term Outcomes After Surgical Pulmonary Arterioplasty and Risk Factors for Reintervention.

Cresalia NM, Armstrong AK, Romano JC, Norris MD, Yu S, Rocchini AP, Zampi JD.

Ann Thorac Surg. 2018 Feb;105(2):622-628. doi: 10.1016/j.athoracsur.2017.06.012. Epub 2017 Sep 28.

PMID:
28964419
14.

High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment.

Heatley SL, Sadras T, Kok CH, Nievergall E, Quek K, Dang P, McClure B, Venn N, Moore S, Suttle J, Law T, Ng A, Muskovic W, Norris MD, Revesz T, Osborn M, Moore AS, Suppiah R, Fraser C, Alvaro F, Hughes TP, Mullighan CG, Marshall GM, Pozza LD, Yeung DT, Sutton R, White DL.

Haematologica. 2017 Dec;102(12):e490-e493. doi: 10.3324/haematol.2016.162925. Epub 2017 Sep 21. No abstract available.

15.

Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo.

Murray J, Valli E, Yu DMT, Truong AM, Gifford AJ, Eden GL, Gamble LD, Hanssen KM, Flemming CL, Tan A, Tivnan A, Allan S, Saletta F, Cheung L, Ruhle M, Schuetz JD, Henderson MJ, Byrne JA, Norris MD, Haber M, Fletcher JI.

Eur J Cancer. 2017 Sep;83:132-141. doi: 10.1016/j.ejca.2017.06.024. Epub 2017 Jul 20.

16.

Temporal relationship between instantaneous pressure gradients and peak-to-peak systolic ejection gradient in congenital aortic stenosis.

Boe BA, Norris MD, Zampi JD, Rocchini AP, Ensing GJ.

Congenit Heart Dis. 2017 Dec;12(6):733-739. doi: 10.1111/chd.12514. Epub 2017 Jul 12.

17.

A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers.

Jung M, Russell AJ, Liu B, George J, Liu PY, Liu T, DeFazio A, Bowtell DD, Oberthuer A, London WB, Fletcher JI, Haber M, Norris MD, Henderson MJ.

Cancer Res. 2017 Feb 15;77(4):971-981. doi: 10.1158/0008-5472.CAN-15-2906. Epub 2016 Dec 6.

18.

The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.

Liu PY, Sokolowski N, Guo ST, Siddiqi F, Atmadibrata B, Telfer TJ, Sun Y, Zhang L, Yu D, Mccarroll J, Liu B, Yang RH, Guo XY, Tee AE, Itoh K, Wang J, Kavallaris M, Haber M, Norris MD, Cheung BB, Byrne JA, Ziegler DS, Marshall GM, Dinger ME, Codd R, Zhang XD, Liu T.

Oncotarget. 2016 Nov 29;7(48):79217-79232. doi: 10.18632/oncotarget.12640.

19.

MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.

Xue C, Yu DM, Gherardi S, Koach J, Milazzo G, Gamble L, Liu B, Valli E, Russell AJ, London WB, Liu T, Cheung BB, Marshall GM, Perini G, Haber M, Norris MD.

Oncotarget. 2016 Aug 23;7(34):54937-54951. doi: 10.18632/oncotarget.10709.

20.

Total Synthesis of Plakilactones C, B and des-Hydroxyplakilactone B by the Oxidative Cleavage of Gracilioether Furanylidenes.

Norris MD, Perkins MV.

J Org Chem. 2016 Aug 5;81(15):6848-54. doi: 10.1021/acs.joc.6b01196. Epub 2016 Jul 21.

PMID:
27359169
21.

CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements.

Somers K, Chudakova DA, Middlemiss SM, Wen VW, Clifton M, Kwek A, Liu B, Mayoh C, Bongers A, Karsa M, Pan S, Cruikshank S, Scandlyn M, Hoang W, Imamura T, Kees UR, Gudkov AV, Chernova OB, Haber M, Norris MD, Henderson MJ.

Oncotarget. 2016 Jul 19;7(29):46067-46087. doi: 10.18632/oncotarget.10022.

22.

MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin.

O'Brien R, Tran SL, Maritz MF, Liu B, Kong CF, Purgato S, Yang C, Murray J, Russell AJ, Flemming CL, von Jonquieres G, Pickett HA, London WB, Haber M, Gunaratne PH, Norris MD, Perini G, Fletcher JI, MacKenzie KL.

Cancer Res. 2016 Jun 15;76(12):3604-17. doi: 10.1158/0008-5472.CAN-15-0879. Epub 2016 Apr 13.

23.

ABC transporters as mediators of drug resistance and contributors to cancer cell biology.

Fletcher JI, Williams RT, Henderson MJ, Norris MD, Haber M.

Drug Resist Updat. 2016 May;26:1-9. doi: 10.1016/j.drup.2016.03.001. Epub 2016 Mar 17. Review.

PMID:
27180306
24.

Structural diversity and chemical synthesis of peroxide and peroxide-derived polyketide metabolites from marine sponges.

Norris MD, Perkins MV.

Nat Prod Rep. 2016 Jul 28;33(7):861-80. doi: 10.1039/c5np00142k. Epub 2016 May 10. Review.

PMID:
27163115
25.

Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.

Evageliou NF, Haber M, Vu A, Laetsch TW, Murray J, Gamble LD, Cheng NC, Liu K, Reese M, Corrigan KA, Ziegler DS, Webber H, Hayes CS, Pawel B, Marshall GM, Zhao H, Gilmour SK, Norris MD, Hogarty MD.

Clin Cancer Res. 2016 Sep 1;22(17):4391-404. doi: 10.1158/1078-0432.CCR-15-2539. Epub 2016 Mar 24.

26.

Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis.

Carter DR, Sutton SK, Pajic M, Murray J, Sekyere EO, Fletcher J, Beckers A, De Preter K, Speleman F, George RE, Haber M, Norris MD, Cheung BB, Marshall GM.

Mol Oncol. 2016 Jun;10(6):866-78. doi: 10.1016/j.molonc.2016.02.004. Epub 2016 Mar 2.

27.

High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients.

Kim PY, Tan O, Liu B, Trahair T, Liu T, Haber M, Norris MD, Marshall GM, Cheung BB.

Cancer Lett. 2016 May 1;374(2):315-23. doi: 10.1016/j.canlet.2016.02.021. Epub 2016 Feb 20.

PMID:
26902425
28.

Gaq signaling is required for the maintenance of MLL-AF9-induced acute myeloid leukemia.

Lynch JR, Yi H, Casolari DA, Voli F, Gonzales-Aloy E, Fung TK, Liu B, Brown A, Liu T, Haber M, Norris MD, Lewis ID, So CW, D'Andrea RJ, Wang JY.

Leukemia. 2016 Aug;30(8):1745-8. doi: 10.1038/leu.2016.24. Epub 2016 Feb 9. No abstract available.

PMID:
26859074
29.

The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression.

Tee AE, Liu B, Song R, Li J, Pasquier E, Cheung BB, Jiang C, Marshall GM, Haber M, Norris MD, Fletcher JI, Dinger ME, Liu T.

Oncotarget. 2016 Feb 23;7(8):8663-75. doi: 10.18632/oncotarget.6675.

30.

Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.

French JD, Johnatty SE, Lu Y, Beesley J, Gao B, Kalimutho M, Henderson MJ, Russell AJ, Kar S, Chen X, Hillman KM, Kaufmann S, Sivakumaran H, O'Reilly M, Wang C, Korbie DJ; Australian Ovarian Cancer Study Group; Australian Ovarian Cancer Study, Lambrechts D, Despierre E, Van Nieuwenhuysen E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching PA, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Pisterer J, Hillemanns P, Nakanishi T, Yatabe Y, Goodman MT, Lurie G, Matsuno RK, Thompson PJ, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan JM, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut JM, Iversen E, Weber RP, Brennan D, Berchuck A, Pharoah P, Harnett P, Norris MD, Haber M, Goode EL, Lee JS, Khanna KK, Meyer KB, Chenevix-Trench G, deFazio A, Edwards SL, MacGregor S; Ovarian Cancer Association Consortium.

Oncotarget. 2016 Feb 9;7(6):6353-68. doi: 10.18632/oncotarget.7047.

31.

Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.

Bassiri H, Benavides A, Haber M, Gilmour SK, Norris MD, Hogarty MD.

Transl Pediatr. 2015 Jul;4(3):226-38. doi: 10.3978/j.issn.2224-4336.2015.04.06. Review.

32.

Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.

Carter DR, Murray J, Cheung BB, Gamble L, Koach J, Tsang J, Sutton S, Kalla H, Syed S, Gifford AJ, Issaeva N, Biktasova A, Atmadibrata B, Sun Y, Sokolowski N, Ling D, Kim PY, Webber H, Clark A, Ruhle M, Liu B, Oberthuer A, Fischer M, Byrne J, Saletta F, Thwe le M, Purmal A, Haderski G, Burkhart C, Speleman F, De Preter K, Beckers A, Ziegler DS, Liu T, Gurova KV, Gudkov AV, Norris MD, Haber M, Marshall GM.

Sci Transl Med. 2015 Nov 4;7(312):312ra176. doi: 10.1126/scitranslmed.aab1803.

33.

Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.

Cheung BB, Tan O, Koach J, Liu B, Shum MS, Carter DR, Sutton S, Po'uha ST, Chesler L, Haber M, Norris MD, Kavallaris M, Liu T, O'Neill GM, Marshall GM.

Mol Oncol. 2015 Aug;9(7):1484-500. doi: 10.1016/j.molonc.2015.04.005. Epub 2015 Apr 29.

34.

MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.

Lau DT, Flemming CL, Gherardi S, Perini G, Oberthuer A, Fischer M, Juraeva D, Brors B, Xue C, Norris MD, Marshall GM, Haber M, Fletcher JI, Ashton LJ.

Oncotarget. 2015 Jun 20;6(17):15510-23.

35.

Folate pathway gene polymorphisms and risk of childhood brain tumors: results from an Australian case-control study.

Greenop KR, Scott RJ, Attia J, Bower C, de Klerk NH, Norris MD, Haber M, Jamieson SE, van Bockxmeer FM, Gottardo NG, Ashton LJ, Armstrong BK, Milne E.

Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):931-7. doi: 10.1158/1055-9965.EPI-14-1248. Epub 2015 Mar 25.

36.

ABC transporters and neuroblastoma.

Yu DM, Huynh T, Truong AM, Haber M, Norris MD.

Adv Cancer Res. 2015;125:139-70. doi: 10.1016/bs.acr.2014.10.005. Epub 2015 Jan 8.

PMID:
25640269
37.

Biomimetic total synthesis of gracilioethers B and C.

Norris MD, Perkins MV, Sorensen EJ.

Org Lett. 2015 Feb 6;17(3):668-71. doi: 10.1021/ol503695j. Epub 2015 Jan 26.

PMID:
25621375
38.

Folate pathway gene polymorphisms, maternal folic acid use, and risk of childhood acute lymphoblastic leukemia.

Milne E, Greenop KR, Scott RJ, Haber M, Norris MD, Attia J, Jamieson SE, Miller M, Bower C, Bailey HD, Dawson S, McCowage GB, de Klerk NH, van Bockxmeer FM, Armstrong BK.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):48-56. doi: 10.1158/1055-9965.EPI-14-0680. Epub 2014 Nov 13.

39.

Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.

Sutton R, Shaw PJ, Venn NC, Law T, Dissanayake A, Kilo T, Haber M, Norris MD, Fraser C, Alvaro F, Revesz T, Trahair TN, Dalla-Pozza L, Marshall GM, O'Brien TA.

Br J Haematol. 2015 Feb;168(3):395-404. doi: 10.1111/bjh.13142. Epub 2014 Oct 14.

PMID:
25312094
40.

GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis.

Dietrich PA, Yang C, Leung HH, Lynch JR, Gonzales E, Liu B, Haber M, Norris MD, Wang J, Wang JY.

Blood. 2014 Nov 20;124(22):3284-94. doi: 10.1182/blood-2013-10-532523. Epub 2014 Oct 7.

41.

An unexpected role for caspase-2 in neuroblastoma.

Dorstyn L, Puccini J, Nikolic A, Shalini S, Wilson CH, Norris MD, Haber M, Kumar S.

Cell Death Dis. 2014 Aug 21;5:e1383. doi: 10.1038/cddis.2014.342.

42.

High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4).

Cheung L, Flemming CL, Watt F, Masada N, Yu DM, Huynh T, Conseil G, Tivnan A, Polinsky A, Gudkov AV, Munoz MA, Vishvanath A, Cooper DM, Henderson MJ, Cole SP, Fletcher JI, Haber M, Norris MD.

Biochem Pharmacol. 2014 Sep 1;91(1):97-108. doi: 10.1016/j.bcp.2014.05.023. Epub 2014 Jun 25.

PMID:
24973542
43.

ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.

Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J; Australian Ovarian Cancer Study Group, Williams RT, Flemming C, Lambrechts D, Despierre E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching P, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Nakanishi T, Yatabe Y, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan J, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut J, Iversen E, Weber RP, Berchuck A, Goode E, Bowtell DD, Chenevix-Trench G, deFazio A, Norris MD, MacGregor S, Haber M, Henderson MJ.

J Natl Cancer Inst. 2014 Jun 23;106(7). pii: dju149. doi: 10.1093/jnci/dju149. Print 2014 Jul.

44.

Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1.

Shahbazi J, Scarlett CJ, Norris MD, Liu B, Haber M, Tee AE, Carrier A, Biankin AV, London WB, Marshall GM, Lock RB, Liu T.

Oncotarget. 2014 Jun 30;5(12):4257-68.

45.

Molecular profiling of childhood cancer: Biomarkers and novel therapies.

Saletta F, Wadham C, Ziegler DS, Marshall GM, Haber M, McCowage G, Norris MD, Byrne JA.

BBA Clin. 2014 Jun 28;1:59-77. doi: 10.1016/j.bbacli.2014.06.003. eCollection 2014 Jun. Review.

46.

The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1.

Tee AE, Ling D, Nelson C, Atmadibrata B, Dinger ME, Xu N, Mizukami T, Liu PY, Liu B, Cheung B, Pasquier E, Haber M, Norris MD, Suzuki T, Marshall GM, Liu T.

Oncotarget. 2014 Apr 15;5(7):1793-804.

47.

Risk for sleep-disordered breathing in adults after atrial switch repairs for d-looped transposition of the great arteries.

Cotts T, Smith KR, Lu J, Dorfman AL, Norris MD.

Pediatr Cardiol. 2014 Jun;35(5):888-92. doi: 10.1007/s00246-014-0873-y. Epub 2014 Feb 7.

PMID:
24504256
48.

Cone reconstruction in children with Ebstein anomaly: the Mayo Clinic experience.

Anderson HN, Dearani JA, Said SM, Norris MD, Pundi KN, Miller AR, Cetta ML, Eidem BW, O'Leary PW, Cetta F.

Congenit Heart Dis. 2014 May-Jun;9(3):266-71. doi: 10.1111/chd.12155. Epub 2013 Dec 23.

PMID:
24373319
49.

Identification of plasma complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach.

Kim PY, Tan O, Diakiw SM, Carter D, Sekerye EO, Wasinger VC, Liu T, Kavallaris M, Norris MD, Haber M, Chesler L, Dolnikov A, Trahair TN, Cheung NK, Marshall GM, Cheung BB.

J Proteomics. 2014 Jan 16;96:1-12. doi: 10.1016/j.jprot.2013.10.032. Epub 2013 Nov 4.

50.

Improving the identification of high risk precursor B acute lymphoblastic leukemia patients with earlier quantification of minimal residual disease.

Karsa M, Dalla Pozza L, Venn NC, Law T, Shi R, Giles JE, Bahar AY, Cross S, Catchpoole D, Haber M, Marshall GM, Norris MD, Sutton R.

PLoS One. 2013 Oct 11;8(10):e76455. doi: 10.1371/journal.pone.0076455. eCollection 2013.

Supplemental Content

Loading ...
Support Center